Sigma-Aldrich — Q1 2012 Earnings Presentation
17 slides from Sigma-Aldrich's earnings presentation, Apr 24, 2012
Slide 1: Sigma-Aldrich Corporation Q1 2012 Earnings Review & Outlook
• Sigma-Aldrich Corporation Q1 2012 Earnings Review & Outlook Enabling Science to Improve the Quality of Life sigma-aldrich.com Exhibit 99.2
Slide 2: Cautionary Statements
• • Cautionary Statements O ur presentation today may include forward-looking statements within the meaning of Section 27A of the Securities Act of and Section 21E of the Securities Exchange Act of 1934. Such statements involve risk and uncertainty, including financial, business environment and proj
Slide 3: 1st Quarter 2012 Financial Results
YEAR-OVER-YEAR Sales of $665 Million Increase 5% Over Last Year Sales and Operating Income New Quarterly Highs YEAR-OVER-YEAR 1st Quarter 2012 Financial Results ($ in millions, except per share amounts) As Reported Q1 2012 As Reported Excluding Special Items Operating Income $ 172 3% 4% Net Income $
Slide 4: Sales Mix (QTD) Organic Sales Growth in Line with Expectations
Sales Mix (QTD) Organic Sales Growth in Line with Expectations 2012 Sales Growth RESEARCH 70% 30% SAFC 4% 1% 3% Research SAFC Total Company Organic* Reported 4% 9% 5% Q1 2012 / Q1 2011 *See Slide 16 for Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth. 2% 9% 4% Acquisitions
Slide 5: Growth Initiatives Collectively on Track
00 Growth. Initiatives Collectively on Track Q1 2012 Sales Performance Highlight Innovation Reported Organic (1) • Analytical, Biology, Materials Science Sales Growth (2) 4-8% 3-9% Geographic Growth • North America 5% 1% • Europe 1% 2% • Asia Pacific/Latin America 13% 9% • Focus Markets – India, Chi
Slide 6: Adjusted Operating Margin Analysis
Adjusted Operating Margin, Excluding the Impact of Acquisitions, Improved 00 Reported Operating Income Margin to Adjusted Operating Income Ma rgin. 26.6% Margin Analysis PERCENTAGE OF SALES Q1 2012 Adjusted Operating Income Margin – Q1 26.9% Adjusted Operating Income Before Acquisitions (1) (1) (1)
Slide 7: Free Cash Flow: Working Capital and Capital Expenditures Increase
3 Months Ended March 31 Working Capital and Capital Expenditures Increase to Support Sales Growth and Improve Operational Efficiency Free Cash Flow (in millions) $ 117 (56) (32) $ 112 Net Income Free Cash Flow Net Cash Provided by Operating Activities Less Capital Expenditures Other Changes in Perfo
Slide 8: First Quarter 2012 Highlights
Q1 Results Meet Expectations; Acquisition and New Capacity to Boost Sales Growth • Record quarter for sales and earnings • Acquisition of BioReliance and Research Organics • New Capacity First Quarter 2012 Highlights
Slide 9: Sigma-Aldrich Positioned to Capitalize on These Market Trends
Sigma-Aldrich Positioned to Capitalize on These Market Trends • Macro-economic Pressures • Industry Consolidation • Outsourcing in Pharmaceutical • Emerging Market Growth • Shift to Biologics • Applied Markets Growth Key Trends Drive Opportunities
Slide 10: Organic Sales Growth and EPS Outlook Reaffirmed
Organic Sales Growth and EPS Outlook Reaffirmed 2012 Guidance Organic Sales Growth 1st Half Mid Single-digit 2nd Half Full Year Low Double-digits Low to Mid Single-digit Research SAFC Mid Single-digit Low to Mid Single-digit Diluted Adjusted EPS* Free Cash Flow $ 3.90 to $ 4.05 Approximately $425M *
Slide 11: Questions?
QUESTIONS? Sigma-Aldrich Corporation Q1 2012 Earnings Review
Slide 12: Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures
Appendix Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 13: Net Income and Diluted Earnings Per Share to Adjusted
Reconciliation of Reported Net Income and Diluted Earnings Per Share to Adjusted Net Income and Adjusted Diluted Earnings Per Share (Unaudited) Reported net income $ $ 0.96 $ 0.97 $ Acquisition transaction costs - 0.03 - Restructuring costs - - 0.01 Tax Benefit - (5) - (0.04) Adjusted net income $ $
Slide 14: Operating Income to Adjusted Operating Income
Reconciliation of Reported Operating Income to Adjusted Operating Income (Unaudited) Reported operating income $ $ Acquisition transaction costs - Restructuring costs - Adjusted operating income $ $ Reported operating income margin 25.9% 26.4% Acquisition transaction costs 0.7% - Restructuring costs
Slide 15: Sales Growth to Adjusted (Organic) Sales Growth
Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth (Unaudited) Three Months Ended March 31, Reported FX Impact Acquisitions Organic • Analytical, Biology, Materials Science Sales Growth Geographic Growth • North America • Europe • Asia Pacific/Latin America • Focus Markets –
Slide 16: Sales Growth to Adjusted (Organic) by Business Unit
Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth (Unaudited) Sales Growth by Business Unit Currency Acquisition Adjusted Reported Benefit Benefit (Organic) Research Chemicals 4% (2%) 2% 4% SAFC 9% (1%) 9% 1% Total Customer Sales 5% (2%) 4% 3% Three Months Ended March 31, 20
Slide 17: Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited) In millions Net cash provided by operating activities $ $ Less: Capital expenditures (32) (18) Free cash flow $ $ March 31, Three Months Ended